|Other Names||Low-density lipoprotein receptor-related protein 12, LRP-12, Suppressor of tumorigenicity 7 protein, LRP12, ST7|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6251a was selected from the C-term region of human ST7 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Probable receptor, which may be involved in the internalization of lipophilic molecules and/or signal transduction. May act as a tumor suppressor.|
|Cellular Location||Membrane; Single-pass type I membrane protein Membrane, coated pit|
|Tissue Location||Widely expressed in heart, skeletal muscle, brain, lung, placenta and pancreas, but not in tissues consisting of a large number of epithelial cells, such as liver and kidney Expressed at very low levels in a number of tumor-derived cell lines.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ST7 was identified by its differential expression in cancer cells. The product of this gene is predicted to be a transmembrane protein. The level of this protein was found to be lower in tumor derived cell lines compared to normal cells. This protein has thus been proposed to be a candidate tumor suppressor gene.
Battle, M.A., et al., Biochemistry 42(24):7270-7282 (2003).Qing, J., et al., Oncogene 18(2):335-342 (1999).Kleiderlein, J.J., et al., Hum. Genet. 103(6):666-673 (1998).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.